Terms: = Head and neck cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
354 results:
1. [Phase Ⅱ clinical trial of pd-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
[No Abstract] [Full Text] [Related]
2. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-pd-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract] [Full Text] [Related]
3. RNA splicing regulator EIF3D regulates the tumor microenvironment through immunogene-related alternative splicing in head and neck squamous cell carcinoma.
Lu D; Mihoayi M; Ablikim Y; Arikin A
Aging (Albany NY); 2024 Mar; 16(7):5929-5948. PubMed ID: 38535990
[TBL] [Abstract] [Full Text] [Related]
4. M6A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma.
Wang Y; Peng L; Wang F
Cancer Biol Ther; 2024 Dec; 25(1):2333590. PubMed ID: 38532632
[TBL] [Abstract] [Full Text] [Related]
5. Treatments on the horizon for locally advanced basal cell carcinoma.
Idriss MH; Stull CM; Migden MR
Cancer Lett; 2024 May; 589():216821. PubMed ID: 38521198
[TBL] [Abstract] [Full Text] [Related]
6. Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of head and neck Squamous Cell Carcinoma.
Zhou R; Wang J
Crit Rev Immunol; 2024; 44(4):61-78. PubMed ID: 38505922
[TBL] [Abstract] [Full Text] [Related]
7. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
8. Immune checkpoint CD161/LLT1-associated immunological landscape and diagnostic value in oral squamous cell carcinoma.
Hu X; Dong Y; Xie S; Song Y; Yu C; He Y; Wang Z; Hu Q; Ni Y; Ding L
J Pathol Clin Res; 2024 Mar; 10(2):e353. PubMed ID: 38502058
[TBL] [Abstract] [Full Text] [Related]
9. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
Front Immunol; 2024; 15():1302903. PubMed ID: 38500886
[TBL] [Abstract] [Full Text] [Related]
10. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract] [Full Text] [Related]
11. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract] [Full Text] [Related]
12. Perioperative immunotherapy for esophageal squamous cell carcinoma.
Wei DD; Fang JM; Wang HZ; Chen J; Kong S; Jiang YY; Jiang Y
Front Immunol; 2024; 15():1330785. PubMed ID: 38440724
[TBL] [Abstract] [Full Text] [Related]
13. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
[TBL] [Abstract] [Full Text] [Related]
14. Clinical significance of integrin αV and β superfamily members and focal adhesion kinase activity in oral squamous cell carcinoma: a retrospective observational study.
Sakurai S; Ishida Y; Shintani T; Yamasaki S; Matsui K; Hamana T; Nobumoto T; Yanamoto S; Hayashido Y
Pathol Oncol Res; 2024; 30():1611571. PubMed ID: 38312516
[No Abstract] [Full Text] [Related]
15. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract] [Full Text] [Related]
16. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Hosonuma M; Hirasawa Y; Kuramasu A; Murayama M; Narikawa Y; Toyoda H; Baba Y; Isobe J; Funayama E; Tajima K; Shida M; Hamada K; Tsurui T; Ariizumi H; Ishiguro T; Suzuki R; Ohkuma R; Kubota Y; Horiike A; Sambe T; Tsuji M; Wada S; Kiuchi Y; Kobayashi S; Tsunoda T; Yoshimura K
Cancer Sci; 2024 Mar; 115(3):752-762. PubMed ID: 38254257
[TBL] [Abstract] [Full Text] [Related]
17. A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients.
Wu YX; Tian BY; Ou XY; Wu M; Huang Q; Han RK; He X; Chen SL
Cancer Immunol Immunother; 2024 Jan; 73(1):14. PubMed ID: 38236288
[TBL] [Abstract] [Full Text] [Related]
18. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
Le Meitour Y; Foy JP; Guinand M; Michon L; Karabajakian A; Fayette J; Saintigny P; Mahtouk K
Oral Oncol; 2024 Feb; 149():106680. PubMed ID: 38218022
[TBL] [Abstract] [Full Text] [Related]
19. Immunophenotyping with high-dimensional flow cytometry identifies Treg cell subsets associated with recurrence in papillary thyroid carcinoma.
Li S; Chen Z; Liu M; Li L; Cai W; Lian ZX; Guan H; Xu B
Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38214937
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PandA trial.
Verschoor YL; van de Haar J; van den Berg JG; van Sandick JW; Kodach LL; van Dieren JM; Balduzzi S; Grootscholten C; IJsselsteijn ME; Veenhof AAFA; Hartemink KJ; Vollebergh MA; Jurdi A; Sharma S; Spickard E; Owers EC; Bartels-Rutten A; den Hartog P; de Miranda NFCC; van Leerdam ME; Haanen JBAG; Schumacher TN; Voest EE; Chalabi M
Nat Med; 2024 Feb; 30(2):519-530. PubMed ID: 38191613
[TBL] [Abstract] [Full Text] [Related]
[Next]